Based on: Major Depressive Disorder — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 49 candidate interventions for major Depressive Disorder that are either approved medicines or have at least one registered clinical trial, built on 14 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 6 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- escitalopram — 5 registered trials · approved medicine · NCT01034995 NCT00166114 NCT00464711
- BMS-820836 — 4 registered trials · investigational · NCT01369095
- Duloxetine — 3 registered trials · approved medicine · NCT00331799 NCT01369095 NCT00062673
- Fluoxetine — 2 registered trials · approved medicine · NCT00332787 NCT00018057
- Cognitive Behavioral Therapy — 2 registered trials · investigational · NCT00018057 NCT02883257
- Desipramine — 1 registered trial · approved medicine · NCT00166114
- Paroxetine — 1 registered trial · approved medicine · NCT00457106
- Zuranolone — 1 registered trial · approved medicine · NCT05655507
- 18FAV45 — 1 registered trial · investigational · NCT01962753
- amibegron (SR58611A) — 1 registered trial · investigational · NCT00385307
- Antidepressant medication — 1 registered trial · investigational · NCT05002309
- Anyu Peibo — 1 registered trial · investigational · NCT03183505
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in major Depressive Disorder and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: BDNF, CRH, DRD2, FKBP5, GRIN2B, HTR1A, HTR2A, IL6, MAOA, MAOB, NTRK2, SLC6A2, SLC6A3, SLC6A4.
Which trials are registered?
- Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder NCT07282678 · Recruiting · Phase NA · started 2026-09
- A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression NCT07300969 · Recruiting · Phase PHASE2 · started 2025-12-16
- Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets NCT05046184 · Completed · Phase PHASE2 · started 2022-05-05
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder NCT03065335 · Recruiting · Phase PHASE1 · started 2017-05-25
- Evaluation of the Genetics of Bipolar Disorder NCT00001174 · Completed · started 1994-08-11
- IMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition NCT07197138 · Recruiting · Phase NA · started 2025-09-11
- NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder NCT05669703 · Recruiting · started 2023-11-03
- Epigenetic Enhancement of Cognitive Training in Aging Mood and Schizophrenia Spectrum Disorder Populations NCT07404085 · Recruiting · Phase NA · started 2025-11-14
- A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder NCT07775300 · Recruiting · Phase PHASE3 · started 2026-08-14
- Stress Management and Meditative Movements for Asian Americans With Depression and Physical Symptoms NCT07610928 · Recruiting · Phase NA · started 2026-09-01
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.